Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: August 31, 2009
Last updated: September 3, 2014
Last verified: September 2014

Postmenopausal women will receive testosterone gel or matching placebo gel daily. Sebum excretion rates will be measured before and after 6 weeks of treatment.

Condition Intervention Phase
Skin Androgenization
Drug: testosterone gel
Drug: Comparator: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Diagnostic
Official Title: A Pilot Study to Investigate Biomarkers of Skin Androgenization Following Short-Term Testosterone Administration in Healthy Postmenopausal Women

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • serum free testosterone concentrations following multiple doses of AndroGel [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • mean percent change from baseline in sebum excretion [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: October 2004
Study Completion Date: June 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
2.5 mg testosterone gel
Drug: testosterone gel
300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
Other Name: AndroGel
Experimental: 2
300 ug testosterone gel
Drug: testosterone gel
300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
Other Name: AndroGel
Placebo Comparator: 3
placebo gel
Drug: Comparator: placebo
transdermal placebo gel for 6 weeks


Ages Eligible for Study:   50 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is at least 3 years postmenopausal
  • Subject is in good general health
  • Subject is willing to avoid excess alcohol or strenuous physical activity during the study

Exclusion Criteria:

  • Subject has donated a unit of blood or has taken an investigational drug in another clinical trial in the last 4 weeks
  • Subject is a regular user of any illicit drugs
  • Subject drinks excessive amounts of coffee, tea or cola
  • Subject has used an estrogen or progestogens hormone replacement therapy in the past 6 months
  • Subject has a history of cancer
  • Subject has acne
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00969163

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00969163     History of Changes
Other Study ID Numbers: 0000-015, MK0000-015, 2009_654
Study First Received: August 31, 2009
Last Updated: September 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
Biomarkers of Skin Androgenization

Additional relevant MeSH terms:
Signs and Symptoms
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Anabolic Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2014